Asymmetrex Says to Intellia Therapeutics, “Don’t Forget the Stem Cells. Call Us”

by Asymmetrex on August 23, 2016

The biotech medicine world has been waiting to hear from new gene-editing companies exactly how they will go about turning the highly touted research advance into an effective medical advance. If reports about gene-editing company Intellia Therapeutics’ plan are any indication of the approach that will be taken, there is a rocky road ahead for sure.

Intellia seems to be following the approach of companies like Alnylam by focusing first on getting efficient transfer of their gene-editing machines into liver cells.  This approach has worked well so far for Alnylam in early clinical trials designed to reduce the levels of disease-causing proteins by blocking their production with RNAi molecules.  However, Intellia seems to be overlooking a very fundamental difference between Alnylam’s RNAi drugs and Intellia’s gene-editing “drugs.”

Alnylam’s drugs work directly in mature liver cells.  If they need repeated dosing, there is nothing inherent in their action that would preclude continued dosing for a patient’s lifetime.  In contrast, Intellia would be quite concerned if they needed to do multiple dosing because their gene-editing machines could make quite a bit of trouble, even potentially disrupting earlier edits.  But, Intellia is reporting now because they are quite pleased by how effective their molecular machines seem to be at editing a targeted gene expressed abundantly by mature liver cells.

Here at Asymmetrex, we were looking for one more crucial piece of information for Intellia.  Intellia does not report how long the editing effect lasts.  If they have only targeted mature liver cells, it will not last for long.  In about 200 days, ALL of the mature cells in the liver are replaced by new mature cells produced by the division of liver tissue stem cells.  If the liver is injured (e.g., by other medicines, dietary toxins, or infection), the replacement of mature liver cells can be even faster.  So, to achieve long lasting gene-editing therapy and avoid the need for undesirable multiple dosing, Intellia must put its gene-editing machines into liver tissue stem cells.  Alnylam’s drugs don’t have this requirement.

The liver has one of the highest estimated stem cell fractions.  But, still, only about one in 250 cells are estimated to be stem cells.  So, getting a high fraction of them edited is a certain challenge in the future of Intellia.  Since there are no specific markers reported that would allow targeting gene-editing machines to liver stem cells and not mature liver cells, the road ahead is even rockier.  However, there is one company that has a path to the discovery of such markers, which may be crucial to Intellia’s success. Asymmetrex is waiting for their call. 

Read More
AsymmetrexAsymmetrex Says to Intellia Therapeutics, “Don’t Forget the Stem Cells. Call Us”

Asymmetrex Offers Contract Service For Counting Adult Tissue Stem Cells

by Asymmetrex on August 23, 2016

During the fall regenerative medicine and pharmaceutical conference seasons, Boston biotechnology company Asymmetrex, LLC will announce its new contract service for counting adult tissue stem cells. In three different conference venues, the company will relate how its new AlphaSTEM Test service can provide, for the first time, stem cell dose data for stem cell treatments and provide early identification of drug candidates destined to fail in clinical trials because they are toxic to tissue stem cells.

At its company website, Asymmetrex has reported data showing its success in determining the number of stem cells from three different types of human tissues, including bone marrow, liver, and lungs. The stem cell counting technology is based on computer simulation analyses of basic cell count data. Recent refinements in the software allow Asymmetrex to also determine tissue stem cell number using published cell count data from human tissue cell cultures. This new capability will allow the company to rapidly increase its experience with counting stem cells in many different human tissues. Most recently, this approach has been used to estimate the number of tissue stem cells in amniotic fluid cell preparations for first time.

The AlphaSTEM Test is also a powerful new tool for the pharmaceutical industry. Now being able to monitor the effects of drug candidates on stem cell number and function, it is possible to identify stem cell-toxic drugs in relatively inexpensive cell culture formats. Stem cell-toxic drugs cause chronic organ failure in animals and people. The new Asymmetrex service can provide significant savings to pharmaceutical companies by earlier identification of stem cell-toxic drugs that will fail later in animal studies and clinical trials, which are much more expensive. Estimates suggest that such failures cost the U.S. pharmaceutical industry 4 to 5 billion dollars each year.

This fall, Asymmetrex will introduce its new stem cell counting contract service to important industry audiences in three different conference forums. Two of the conferences will take place in Boston. The third is a global web-based conference. The web conference, organized by Euroscicon Life Sciences Events, addresses “Moving Forward With Stem Cell Therapy.” Scheduled for September 6-8, it is the first live-streamed only, three day professional conference to discuss cellular therapies. Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., will discuss how the ability to count tissue stem cells will change forever the practice of stem cell medicine and tissue stem cell research.

Director Sherley will give a second presentation at BioPharm America 2016 that occurs September 13-15. In addition, to giving a talk on the new AlphaSTEM Test service, he has invited representatives from more than 70 pharmaceutical companies to join him in one-on-one meetings to learn about the new technology and how it can significantly improve their bottom lines each year.

A third presentation will be made at a new addition to the clinical trials conference landscape. The Arena International 1st Annual Preclinical Development Operations Summit will take place in Boston November 15-16. In addition to introducing Asymmetrex’s new tissue stem counting contract service, Director Sherley will discuss how beginning now to implement stem cell counting procedures in preclinical development operations for regenerative medicine will prepare companies for an inevitable future of the FDA mandating stem cell dosing data.

“Asymmetrex has the good fortune of having developed a technology whose time is now.” Director Sherley refers to current increased attention to some new and some longstanding challenges in stem cell medicine. The FDA is under increasing pressure to do something about now hundreds, and maybe thousands, of stem cell treatment clinics that inject patients without knowing the number or quality of stem cells. However, FDA-approved clinical trials are allowed to proceed, even though they also lack the same crucial information. The National Institute of Standards and Technology (NIST) recently launched a program to develop new technologies for standardizing cell measurements. First in the U.K. and now in the U.S., there are new initiatives by drug regulation agencies to reduce the number of animals used for drug evaluations. Worldwide there are many hundreds of thousands of banked umbilical cord blood samples that contain blood stem cells needed to treat diseases like childhood leukemia; but there is no method in use to determine the stem cell potency of these potentially life saving cells.

In the scheduled fall forums, Director Sherley will discuss with these three diverse industry audiences how Asymmetrex’s new AlphaSTEM Test contract service is the solution for each of these challenges, which they currently face daily.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

Read More
AsymmetrexAsymmetrex Offers Contract Service For Counting Adult Tissue Stem Cells

New Volume on Human Stem Cell Toxicology Debuts Today

by Asymmetrex on August 11, 2016

Asymmetrex Director Edits Newly Released Book on Human Stem Cell Toxicology

 

Today, August 11, 2016, Royal Society of Chemistry Publishing in the UK released a new volume that is a first scholarly treatment of the emerging research and medical discipline of human stem cell toxicology. The 175 years old organization, which is the oldest chemical society in the world, enlisted Dr. James L. Sherley, the founder and director of Asymmetrex, LLC in the US, to develop and edit the new text.

Human Stem Cell Toxicology debuts today from the revered publishing house of the Royal Society of Chemistry in the United Kingdom. As a first publication of a collection of scholarly treatments of this increasingly important topic in environmental health sciences and stem cell medicine, the new book meets very well the RSC standard of advancing excellence in the chemical sciences, including related fields like biology and medicine. The new volume is an unparalleled collection of scholarly exposés, written by leading international experts, selected to highlight the essential challenges, recent progress, and future vision of the emerging field of toxicology for human tissue stem cells.

RSC contracted Asymmetrex director James L. Sherley, M.D., Ph.D. to develop and edit the new volume. Sherley, who has multidisciplinary research expertise in stem cell biology, stem cell bioengineering, environmental toxicology, and medicine, was well suited for the endeavor. He relates, “The opportunity to create and edit Human Stem Cell Toxicology allowed me to realize a research goal of establishing a more granular appreciation of stem cell biology in the context of environmental toxicology and medicine.” Sherley hopes that readers of the new volume will no longer stammer with uncertainty over the proper use of the terms “stem cell” versus “progenitor cell” versus “stem/progenitor cell.” Although the book’s chapters include significant contents of original research, their explicative introduction, background, discussion sections integrate to provide an effective textbook and reference for students and experts of the discipline, respectively.

Everyone knows fairly well that tissue stem cells are crucial for good health. But this understanding is mostly grounded by the concept that when stem cells go awry, disease and illness result. The other side of this coin of understanding is not as widely appreciated. It is that things that harm tissue stem cells will be harbingers of disease and even death. This second perspective is the province of human stem cell toxicology.

A guiding principle of Human Stem Cell Toxicology is the recognition that the same research challenges that slow progress in stem cell medicine also slow progress in developing needed stem cell toxicology applications. These long-standing unmet research challenges are difficulty producing tissue stem cells and difficulty quantifying tissue stem cells, which are essential advances needed to engineer new tests for investigating and evaluating stem cell toxicity.

The authors in Human Stem Cell Toxicology present innovative strategies for achieving new stem cell toxicity tests that can resolve the main application needs of the field. These applications include identifying hazardous toxicants and toxins in the environment, screening out toxic drug candidates during pharmaceutical drug development, and discovery of drugs for eradicating unwanted tissue stem cells like cancer stem cells.

The new volume also holds some surprises for the world of human toxicology. Although grounded in the core principles of toxicology, examples of surprises include the introduction of new concepts like “kinetoxicity;” introduction of both direct and indirect mechanisms by which toxins and toxicants disrupt normal tissue stem cell function; and the disclosure of the toxicology of a recently discovered new type of tissue stem cell that exhibits remarkable toxicity from commonly used, and even household, medicines. Perhaps, most surprising is the absence of any description of Asymmetrex’s newest technology that solves the tissue stem cell quantification problem to enable a new assay for identifying tissue stem cell-toxic drug candidates. Sherley jokes, “I’m saving that for Human Stem Cell Toxicology II!”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.

BOSTON, MA (PRWEB) AUGUST 11, 2016

Read More

AsymmetrexNew Volume on Human Stem Cell Toxicology Debuts Today

Asymmetrex Continues to Court Gene-Editing Companies

by Asymmetrex on April 28, 2016

Asymmetrex continues to court gene-editing companies; Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics to name a few.  Asymmetrex wants to dance with these companies into the new era of gene-editing therapeutics.  Asymmetrex started pursuing them late in 2015.  Today, the company announced that it would begin courting the companies’ scientists at conferences focused on gene-editing research and progress to clinical trials.  Asymmetrex holds keys to two locks that currently bar the door to efficient and efficacious gene-editing.  In order for gene-editing therapy to work, the DNA-editing must be performed in rare and hard to quantify tissue stem cells.  Asymmetrex’s patented SACK technology can increase the number of targeted tissue stem cells, making their editing more efficient.  Asymmetrex’s AlphaSTEM technology will allow gene editors to determine whether sufficient tissue stem cells are present for effective editing and whether sufficient tissue stem cells have been edited for stable, efficacious therapy.  Although it is a Sadie Hawkins Day affair at the moment, Asymmetrex is looking forward to these companies wanting to sign its dance card soon.


Asymmetrex Continues Efforts to Raise Awareness of the Importance of Tissue Stem Cell Counting for Advancing Gene-Editing Therapeutics

At a conference on May 4-5, Boston stem cell medicine technology start-up Asymmetrex will target gene-editing scientists directly for relating the importance of incorporating the company’s stem cell counting technology into their work to develop new genetic therapies. The company will also discuss its technologies for expanding natural adult tissue stem cells, which are a rate-limiting factor for successful gene-editing therapeutics.

BOSTON, MA (PRWEB) APRIL 28, 2016

Next week on May 5 at 2:55 pm (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists and other attendees at the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts.

The attention of most gene-editing scientists appears to be focused primarily on well-considered challenges in the DNA-editing technology itself. These are now widely appreciated. They include the usual metrics of the quality of engineered processes: efficiency, sensitivity, specificity, accuracy, precision, and reliability. They also include the all-worrisome unknown unknowns of human biology that may not show up until later in treated patients. However, technological improvements continuously reduce the concern about known challenges, with the expectation that very soon the FDA will accept the first gene-editing clinical trials.

Asymmetrex has its attention on a challenge to gene-editing therapy that becomes important once DNA-editing technology itself is ready for application. This additional challenge is related to the special role of adult tissue stem cells in gene-editing therapy.

Tissue stem cells are the only cells in the body that are long-lived in tissues and organs – on the timescale of the human lifespan – and maintain an open DNA blueprint for cell multiplications that replenish mature functional organ and tissue cells without loss of stem cells. In contrast, mature tissue cells function for only a short period of time – on the order of days to weeks – before they die. Upon dying, they are either sloughed off or reabsorbed followed by disintegration and recycling of their components. So, for effective gene-editing therapy, the editing must take place in the DNA blueprint of tissue stem cells.

All the challenges that stem cells present to stem cell medicine rear-up their problematic heads in gene-editing therapeutics, too. These are scarcity, impurity, difficulty identifying, difficulty counting, and difficulty producing in larger number. Gene-editing companies have tried to get around these problems by engineering molecular vectors that are very efficient at getting into cells and performing gene-editing. But even these strategies would improve significantly with larger numbers of stem cells for editing and knowing the number of stem cells edited.

The ability to expand tissue stem cells and count them, for the first time, is what Asymmetrex can bring to the gene-editing effort. James Sherley, founder and director of Asymmetrex, will give the presentation on May 5. Sherley has contacted some chief executives of gene-editing companies, but he says, “This is a bunch of very focused CEOs! But the first ones to give attention to our technologies for expanding and counting tissue stem cells are going to gain quite an advantage.”

Asymmetrex’s SACK technology employs natural cellular metabolites to induce adult tissue stem cells to multiply exponentially. Its more recently developed AlphaSTEM technology for counting adult tissue stem cells was pioneered with partner AlphaSTAR Corporation. In addition to gene-editing therapeutics, these technologies have many other potential applications in stem cell medicine and drug development. Examples include counting the number of hematopoietic stem cells in umbilical cord blood transplants used for treatment of childhood leukemia and early detection of drug candidates that would later cause organ failure due to tissue stem cell toxicity.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexAsymmetrex Continues to Court Gene-Editing Companies

Asymmetrex Renews Efforts to Help Gene-Editing Companies

by Asymmetrex on April 13, 2016

Asymmetrex Renews Efforts to Help Gene-Editing Companies

Asymmetrex Director James L. Sherley is back to chasing gene-editing companies again.  With the recent announcement of gene-editing company Intellia Therapeutics’ plans to IPO soon, Sherley is even more determined to make sure that gene-editing companies fully appreciate the advantages that Asymmetrex’s technologies for adult tissue stem cells can provide for them.  In order for gene-editing treatments to be stable, the editing must occur in adult tissue stem cells.  Other tissue cell types do not persist in the body long enough to provide permanent cures.  Asymmetrex has recently discussed the importance of being able to count targeted adult tissue stem cells to achieve more efficient gene-editing and to ensure that patients receive gene-edited tissue stem cells. Today, Asymmetrex fired off a series of four tweets to alert Intellia Therapeutics, Editas Medicine, Crispr Therapeutics, and Caribou Biosciences to its SACK technologies for expanding a variety of adult tissue stem cells in culture, including liver (relevant to reports from Intellia), blood, pancreas, and hair follicle stem cells. The more adult tissue stem cells gene-editors have available for editing, the more effective they will be in advancing this exciting new frontier of medicine.

Read More
AsymmetrexAsymmetrex Renews Efforts to Help Gene-Editing Companies

Does Counting Adult Tissue Stem Cells Have a Human Impact?

by Asymmetrex on March 30, 2016

Does Counting Adult Tissue Stem Cells Have a Human Impact?

Asymmetrex’s 3-month campaign to increase awareness of the adult tissue stem cell counting problem has focused on how its AlphaSTEM technology solution could impact research and clinical practice.  Now, the final post in the series answers the question, “Does counting adult tissue stem cells have a human impact?”

Today on RegMedNet, Asymmetrex posted its final comment in a 6-expose series to increase awareness among the international regenerative medicine community of the importance of counting adult tissue stem cells for several different areas of stem cell medicine, drug development, and tissue stem cell research.  The final post emphasizes the immediate human impact of adoption of the company’s new AlphaSTEM technology.  As highlighted on the Asymmetrex website this week, one of the most significant impacts of counting adult tissue stem cells would be immediately starting to reduce the loss and anguish currently endured by families of children treated for leukemia with cord blood samples that may have insufficient blood stem cells for their survival.  Now, the simple act of counting the number of blood stem cells in these samples would make the deaths of many children with this dreaded disease avoidable; and it would free waiting families from the distress and fear that their child might be fated to die because before it was not possible to tell if a cord blood sample had sufficient stem cells. Find more information on the greater human impact of adult tissue stem cell counting on the RegMedNet site.

As its founder and current Director, Dr. Sherley leads Asymmetrex with a mission of advancing emerging adult stem cell tissue technologies to applications in clinical drug discovery and cellular medicine. Asymmetrex is the developer and holder of a rich portfolio of recently issued patents for biotechnologies for the quantification and production of human adult tissue stem cells.

 

 

 

Read More
AsymmetrexDoes Counting Adult Tissue Stem Cells Have a Human Impact?

Saving More Lives from Leukemia by Counting Blood Stem Cells

by Asymmetrex on March 28, 2016

“Leukemia” is a dreaded thing to be told after bringing your child to the doctor because she has become inexplicably tired with a cold that just won’t go away. In the U.S., every year, more than 5000 families hear this cancer name. Thanks to many years of research and clinical investigation, though the treatments are harsh with long-term debilitating side effects, overall survival from leukemia in children and young adults is now about 90%. This high rate of survival is quite an achievement, reflecting the shared efforts of nurses, doctors, counselors, communities, families, and patients. But that remaining lost 10% represents more than 500 real families, each year, destined to face the death of their child. Though medical science and technology may have given the best care available, many of these deaths are not preventable within the present state of knowledge. However, there may be a significant subset of these children for whom a new technology for counting blood stem cells could make a difference.

Many children with leukemia will eventually require a blood stem cell transplant to be cured of their cancer. This need is especially true for a type of leukemia called acute myelogenous leukemia (AML). Essentially all of the nearly 1150 children who present each year in the U.S. with AML will undergo a transplant of either bone marrow or umbilical cord blood, which contain blood stem cells that are crucial for their survival after treatments designed to kill all leukemia cells. These treatments also kill their own blood stem cells that are required for life.

It is in the case of cord blood transplants that counting blood stem cells could ease a lot of anguish and save more children from leukemia. In 2013, there were a reported 931 cord blood transplants performed in the U.S, including 317 for AML, with most being used to treat children. About 10-20% of these transplants failed, resulting in the deaths of 30-60 children with AML. They failed because of insufficient blood stem cells. Cord blood samples have fewer blood stem cells than bone marrow, which has much scarcer donors but a lower failure rate (1-5%). Unfortunately, previously, there has been no way to predict which transplants would fail due to insufficient blood stem cells, because there was no means to count the number of blood stem cells before the transplant.

So today, throughout the country, and the world for that matter, each year hundreds of very sick children wait with their families for more than two months with dread and deep anguish to find out if their cord blood transplant grafted successfully. The simple action of counting the number of blood stem cells in cord blood samples before using them would avoid deaths from inadequate transplants. Not only would this intervention save the lives of 30-60 children, it would eliminate a major source of distress for hundreds of children, their families, and their medical teams.

The current estimate of cord blood samples in the world is 700,000! However, only about 10% may be considered useful, because their total cell count (“TNC”) is below the number currently thought to indicate adequate blood stem cells, which are present in very low amounts. However, the number of blood stem cells present has no established predictive relationship to TNC. Clearly, TNC is in error 10-20% of the time for there being sufficient blood stem cells. All things being equal, it may have a similar error for indicating insufficient blood stem cells. In any case, with a new blood stem cell counting technology available, the clear mandate is to use it to count blood stem cells directly in any cord blood sample that might be used to save a child, or an adult, with leukemia. The same mandate applies to other sources of blood stem cells for transplant treatments. Though transplants with bone marrow or circulating blood that contains blood stem cells have much lower failure rates caused by insufficient blood stem cells, their greater number of transplant treatments (20,000 per year in the U.S.; 68,000 worldwide) result in a number of annual deaths comparable to the number estimated for cord blood transplants.

Read More
AsymmetrexSaving More Lives from Leukemia by Counting Blood Stem Cells

Webinar: Technology for Counting Adult Tissue Stem Cells

by Asymmetrex on March 23, 2016

Webinar: A first technology for counting adult tissue stem cells for applications in regenerative medicine and drug development

Since the first discovery of adult tissue stem cells, it has been impossible to count them. This conundrum persists because neither morphological nor molecular properties have been defined that distinguish tissue stem cells from more abundant committed progenitor cells. This webinar introduced AlphaSTEM, a first-in-class technology with the capability of counting homeostatic stem cells in complex research and therapeutic cell preparations from many different human tissues. The predicted impact of the AlphaSTEM stem cell counting technology on stem cell research, umbilical cord blood bank practice, hematopoietic stem cell transplantation therapies, gene-editing therapeutics, and drug candidate evaluations was considered.  Listen to the webinar on demand now.

What will you learn?

  • The nature of the adult tissue stem cell counting problem
  • How the AlphaSTEM stem cell counting technology works
  • How stem cell counting will impact tissue stem cell research
  • How the determination of “stem cell dose”, for the first time, will impact stem cell transplantation medicine, gene-editing therapeutics, and regenerative medicine research in general
  • How the ability to count tissue stem cells has already enabled assays that identify drug candidates that affect tissue stem cells, negatively, positively, or both

Who may this interest?

  • Research stem cell biologists, university and industry
  • Preclinical drug candidate evaluation CROs
  • Pharmaceutical companies (toxicologists, pharmacovigilance executives)
  • Hematopoietic stem cell transplantation physicians
  • Umbilical cord blood bank directors
  • Gene-editing therapeutic companies
Read More
AsymmetrexWebinar: Technology for Counting Adult Tissue Stem Cells

How AlphaSTEM Technology is used to Count Adult Tissue Stem Cells

by Asymmetrex on March 17, 2016

On March 22, Boston stem cell medicine technology start-up Asymmetrex will present a free, public, online webinar with the goal of discussing how it developed a stem cell technology that has been needed since the beginnings of stem cell biology. Hosted by RegMedNet, a London-based social media network for regenerative medicine professionals, the webinar will provide a first public discussion forum on the company’s new AlphaSTEM technology for counting adult tissue stem cells for the first time.

In a Scheduled March 22 RegMedNet Webinar, Asymmetrex Discusses the Strategy for How AlphaSTEM Technology is used to Count Adult Tissue Stem Cells

BOSTON, MA (PRWEB) MARCH 17, 2016

Asymmetrex, a stem cell medicine technology start-up company headquartered in Boston, began a social media campaign in late 2015 to increase awareness of a long-standing unmet need in stem cell research and stem cell biomedicine. Since the beginnings of stem cell biology in the 1950s, it has not been possible to count adult tissue stem cells. The problem stems from difficulty discovering biomarkers that recognize tissue stem cells, but not their more abundant relatives called committed progenitor cells.

The company has a lot of interest in rekindling attention to this stem cell counting problem, which has existed for so long that some stem cell investigators are unaware of it, some try to work as best they can while knowing it, or some ignore it. Each of these responses undermines the potential of stem cell research and stem cell medicine progress. By providing a solution, Asymmetrex has the potential to improve the quality of stem cell research and greatly accelerate progress in stem cell-based regenerative medicine, including drug development and gene therapies.

Both the educational campaign and the webinar are hosted by the UK social media network RegMedNet. In anticipation of the webinar, RegMedNet posted an audio interview with Asymmetrex Director James Sherley, M.D., Ph.D. on March 14. During the campaign, Director Sherley has posted discussions that describe how the ability to count adult tissue stem cells will transform a wide range of practices in stem cell research, regenerative medicine, drug development, and even environmental health science. Suggested transformations include early identification of drug candidates that would cause organ and tissue failure later in more costly animal studies and clinical trials; evaluation of the stem cell sufficiency of cord blood bank donor samples; determination of the dose of stem cells in transplantation treatments; and increased efficiency and long-term efficacy in gene therapies and gene-editing therapeutics.

In the RegMedNet audio interview, Sherley related the scientific history that culminated in the new AlphaSTEM technology for counting adult tissue stem cells. A key partner in the development of the technology is the statistical modeling and computer simulation leader AlphaSTAR Corp. The two companies are now seeking venture funding to spin out a new company, AlphaSTEM Co., that will further develop and market the new counting technology.

In the upcoming March 22 webinar, Asymmetrex will continue its aim of introducing the attributes of the new technology to the stem cell biology, drug development, regenerative medicine, gene therapy, and gene-editing therapeutics communities. Director Sherley will present the essential elements of the AlphaSTEM method and the results of several experimental validations. Significant time will be allotted for discussion with webinar attendees. The partnering companies are particularly interested in this initial public comment.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

Read More
AsymmetrexHow AlphaSTEM Technology is used to Count Adult Tissue Stem Cells